Unlock stock picks and a broker-level newsfeed that powers Wall Street.

São Paulo - Delayed Quote BRL

CM Hospitalar S/A (VVEO3.SA)

1.2400
+0.0400
+(3.33%)
At close: April 24 at 5:06:00 PM GMT-3
Loading Chart for VVEO3.SA
  • Previous Close 1.2000
  • Open 0.0000
  • Bid 1.2300 x --
  • Ask 1.2400 x --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 5.6500
  • Volume 0
  • Avg. Volume 1,807,832
  • Market Cap (intraday) 391.602M
  • Beta (5Y Monthly) 0.09
  • PE Ratio (TTM) --
  • EPS (TTM) -4.4600
  • Earnings Date --
  • Forward Dividend & Yield 0.14 (11.01%)
  • Ex-Dividend Date May 2, 2024
  • 1y Target Est 2.16

CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers ophthalmic agent, adrenergic and thrombopoietin agonist, aminoglycosides, painkiller, anesthetics, receptor antagonist, anti-hemorrhoidal, antihypertensives, systemic antihistamine, and orthopedic therapy materials; and anti-inflammatories, anti-TNF, antacid, antiandrogen, antianemic, anti-asthmatic, antibiotic, anticoagulant, anticonvulsant, monoclonal antibody, anti-growth, antidepressant, antidiabetic, antidiuretic, antidote, antiemetics and antinauseants, anti-migraine, antiepileptics, antiestrogens, antifibrinolytic, antiflatulent, antifungal, antihemorrhagic, antimicrobial, antineoplastics, antiparathyroid drugs, antiparkinsonian, antipsychotic, systemic antipsoriasis, antirheumatics, anti-varicose, and antiviral medicines. It also provides beta blocker, carbohydrate, cycloplegic, contraceptive, contrast, special control, corticosteroid, topical debrider, diuretic, electrolyte, pancreatic enzyme, erythropoietin, uterine and cardiac stimulant, growth factor, granulocyte colony stimulating factor, gastroprokinetic, systemic hemostatic, heparins, hepatoprotector and lipotropic, hormone, adeno-pituitary and growth hormone, immunoglobulin, immunosuppressant, labor inducer, proton pump and phosphodiesterase inhibitor, bone resorption inhibitor, platelet aggregation inhibitor, adenosine diphosphate receptor antagonist, proton pump and interleukin inhibitor, proprotein convertase subtilisin/kexin type 9 inhibitor, and calcium reabsorption inhibitor medicines. In addition, the company distributes orthopedic products, compression socks, and diapers; and transports medical and hospital cargo. Further, it provides support infrastructure and assistance, as well as pharmaceutical monitoring to patients at home; and wipes and wet towels. CM Hospitalar S/A was founded in 2010 and is headquartered in Ribeirão Preto, Brazil.

www.mafrasaude.com.br

6,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: VVEO3.SA

View More

Performance Overview: VVEO3.SA

Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is IBOVESPA (^BVSP) .

YTD Return

VVEO3.SA
39.51%
IBOVESPA (^BVSP)
11.89%

1-Year Return

VVEO3.SA
78.14%
IBOVESPA (^BVSP)
7.89%

3-Year Return

VVEO3.SA
91.46%
IBOVESPA (^BVSP)
21.16%

5-Year Return

VVEO3.SA
94.47%
IBOVESPA (^BVSP)
78.65%

Compare To: VVEO3.SA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VVEO3.SA

View More

Valuation Measures

Annual
As of 4/24/2025
  • Market Cap

    391.60M

  • Enterprise Value

    3.46B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.03

  • Price/Book (mrq)

    0.20

  • Enterprise Value/Revenue

    0.30

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -12.22%

  • Return on Assets (ttm)

    -5.16%

  • Return on Equity (ttm)

    -54.28%

  • Revenue (ttm)

    11.58B

  • Net Income Avi to Common (ttm)

    -1.42B

  • Diluted EPS (ttm)

    -4.4600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.13B

  • Total Debt/Equity (mrq)

    217.75%

  • Levered Free Cash Flow (ttm)

    -85.56M

Research Analysis: VVEO3.SA

View More

Company Insights: VVEO3.SA

Research Reports: VVEO3.SA

View More

People Also Watch